Saudi Arabia is quickly establishing itself as a major pharmaceutical market, with its Pharmacovigilance (PV) sector forecasted for significant annual growth. At the forefront of this safety landscape is the Saudi Food and Drug Authority (SFDA), which mandates a stringent regulatory framework to ensure robust drug safety monitoring. For Marketing Authorization Holders (MAHs), becoming "SFDA-ready" means building a compliant safety system that meets these rigorous local standards.